Sienna Gestion Sells 4,161 Shares of Amgen Inc. (NASDAQ:AMGN)

Sienna Gestion trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 15.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 22,340 shares of the medical research company’s stock after selling 4,161 shares during the period. Sienna Gestion’s holdings in Amgen were worth $5,822,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Legacy Investment Solutions LLC bought a new stake in Amgen in the 3rd quarter worth about $29,000. Centricity Wealth Management LLC purchased a new position in shares of Amgen during the fourth quarter valued at approximately $25,000. Synergy Investment Management LLC bought a new position in Amgen during the fourth quarter valued at approximately $34,000. Atala Financial Inc purchased a new stake in Amgen in the fourth quarter worth approximately $34,000. Finally, Heck Capital Advisors LLC bought a new stake in Amgen in the 4th quarter worth approximately $36,000. Institutional investors own 76.50% of the company’s stock.

Insider Activity

In related news, EVP David M. Reese sold 25,225 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the firm’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 in the last ninety days. Insiders own 0.69% of the company’s stock.

Amgen Stock Up 0.0 %

NASDAQ AMGN opened at $312.64 on Friday. The stock has a 50 day moving average price of $290.77 and a 200-day moving average price of $299.61. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a market capitalization of $167.95 billion, a P/E ratio of 41.41, a P/E/G ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.05%. Amgen’s dividend payout ratio (DPR) is presently 126.09%.

Analyst Ratings Changes

A number of research firms have recently issued reports on AMGN. Wells Fargo & Company restated an “equal weight” rating on shares of Amgen in a research note on Wednesday, February 5th. Truist Financial dropped their target price on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research report on Wednesday, January 8th. Piper Sandler upped their price target on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Leerink Partners lowered their price objective on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Finally, UBS Group reaffirmed a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Amgen has an average rating of “Hold” and a consensus price target of $314.04.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.